vs
Side-by-side financial comparison of Borealis Foods Inc. (BRLS) and ClearPoint Neuro, Inc. (CLPT). Click either name above to swap in a different company.
ClearPoint Neuro, Inc. is the larger business by last-quarter revenue ($10.4M vs $7.1M, roughly 1.5× Borealis Foods Inc.). On growth, ClearPoint Neuro, Inc. posted the faster year-over-year revenue change (34.0% vs -12.0%). Over the past eight quarters, ClearPoint Neuro, Inc.'s revenue compounded faster (16.7% CAGR vs -2.4%).
Borealis Foods Inc is a food technology enterprise specializing in developing and producing high-quality plant-based protein products including plant-based meat alternatives. It mainly serves retail and food service customers across North America and Europe, focusing on delivering affordable, nutritious sustainable food options matching the taste of conventional animal-derived meat.
ClearPoint Neuro, Inc. is a medical technology firm specializing in precision neurology solutions. It develops and commercializes intraoperative navigation, targeting and delivery systems for minimally invasive brain surgeries, neurological disorder treatments, and CNS therapy development for global clinical and biopharmaceutical partners.
BRLS vs CLPT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.1M | $10.4M |
| Net Profit | $-3.8M | — |
| Gross Margin | 14.6% | 61.5% |
| Operating Margin | -27.1% | -67.7% |
| Net Margin | -53.2% | — |
| Revenue YoY | -12.0% | 34.0% |
| Net Profit YoY | 21.8% | — |
| EPS (diluted) | $-0.18 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $10.4M | ||
| Q3 25 | $7.1M | $8.9M | ||
| Q2 25 | $7.2M | $9.2M | ||
| Q1 25 | $6.8M | $8.5M | ||
| Q4 24 | $6.8M | $7.8M | ||
| Q3 24 | $8.1M | $8.1M | ||
| Q2 24 | $5.5M | $7.9M | ||
| Q1 24 | $7.9M | $7.6M |
| Q4 25 | — | — | ||
| Q3 25 | $-3.8M | $-5.9M | ||
| Q2 25 | $-4.6M | $-5.8M | ||
| Q1 25 | $-4.2M | $-6.0M | ||
| Q4 24 | $-5.8M | — | ||
| Q3 24 | $-4.8M | $-5.0M | ||
| Q2 24 | $-6.3M | $-4.4M | ||
| Q1 24 | $-8.4M | $-4.1M |
| Q4 25 | — | 61.5% | ||
| Q3 25 | 14.6% | 63.2% | ||
| Q2 25 | 7.2% | 60.3% | ||
| Q1 25 | 13.1% | 60.5% | ||
| Q4 24 | 3.7% | 61.3% | ||
| Q3 24 | 15.8% | 59.7% | ||
| Q2 24 | 7.7% | 63.5% | ||
| Q1 24 | 3.1% | 59.2% |
| Q4 25 | — | -67.7% | ||
| Q3 25 | -27.1% | -59.5% | ||
| Q2 25 | -46.7% | -61.6% | ||
| Q1 25 | -42.6% | -72.6% | ||
| Q4 24 | -68.4% | -72.5% | ||
| Q3 24 | -44.8% | -63.5% | ||
| Q2 24 | -94.8% | -60.1% | ||
| Q1 24 | -88.3% | -55.2% |
| Q4 25 | — | — | ||
| Q3 25 | -53.2% | -66.5% | ||
| Q2 25 | -64.0% | -63.3% | ||
| Q1 25 | -61.2% | -71.0% | ||
| Q4 24 | -85.3% | — | ||
| Q3 24 | -59.8% | -61.2% | ||
| Q2 24 | -115.0% | -56.1% | ||
| Q1 24 | -106.8% | -54.3% |
| Q4 25 | — | $-0.26 | ||
| Q3 25 | $-0.18 | $-0.21 | ||
| Q2 25 | $0.21 | $-0.21 | ||
| Q1 25 | $-0.20 | $-0.22 | ||
| Q4 24 | $-0.82 | $-0.20 | ||
| Q3 24 | $-0.23 | $-0.18 | ||
| Q2 24 | $0.29 | $-0.16 | ||
| Q1 24 | $-0.49 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $45.9M |
| Total DebtLower is stronger | — | $49.1M |
| Stockholders' EquityBook value | $-12.9M | $28.0M |
| Total Assets | $56.3M | $97.7M |
| Debt / EquityLower = less leverage | — | 1.75× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $45.9M | ||
| Q3 25 | — | $38.2M | ||
| Q2 25 | — | $41.5M | ||
| Q1 25 | — | $12.4M | ||
| Q4 24 | — | $20.1M | ||
| Q3 24 | — | $21.6M | ||
| Q2 24 | — | $32.8M | ||
| Q1 24 | — | $35.4M |
| Q4 25 | — | $49.1M | ||
| Q3 25 | — | $29.2M | ||
| Q2 25 | — | $28.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $10.0M | ||
| Q1 24 | — | $10.0M |
| Q4 25 | — | $28.0M | ||
| Q3 25 | $-12.9M | $15.9M | ||
| Q2 25 | $-9.2M | $19.7M | ||
| Q1 25 | $-4.8M | $20.0M | ||
| Q4 24 | $-695.9K | $25.4M | ||
| Q3 24 | $5.1M | $29.0M | ||
| Q2 24 | $9.9M | $32.1M | ||
| Q1 24 | $16.2M | $34.6M |
| Q4 25 | — | $97.7M | ||
| Q3 25 | $56.3M | $60.4M | ||
| Q2 25 | $57.3M | $62.9M | ||
| Q1 25 | $58.4M | $30.1M | ||
| Q4 24 | $60.0M | $39.2M | ||
| Q3 24 | $61.9M | $40.2M | ||
| Q2 24 | $63.6M | $52.6M | ||
| Q1 24 | $70.3M | $53.6M |
| Q4 25 | — | 1.75× | ||
| Q3 25 | — | 1.84× | ||
| Q2 25 | — | 1.46× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.31× | ||
| Q1 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-190.6K | $-12.1M |
| Free Cash FlowOCF − Capex | — | $-12.1M |
| FCF MarginFCF / Revenue | — | -116.5% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-24.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-12.1M | ||
| Q3 25 | $-190.6K | $-3.1M | ||
| Q2 25 | $-2.2M | $-2.6M | ||
| Q1 25 | $-1.4M | $-6.2M | ||
| Q4 24 | $-819.4K | $-1.2M | ||
| Q3 24 | $-3.3M | $-1.2M | ||
| Q2 24 | $-4.2M | $-2.7M | ||
| Q1 24 | $-6.8M | $-3.8M |
| Q4 25 | — | $-12.1M | ||
| Q3 25 | — | $-3.3M | ||
| Q2 25 | — | $-2.6M | ||
| Q1 25 | $-1.4M | $-6.4M | ||
| Q4 24 | $-951.6K | $-1.5M | ||
| Q3 24 | $-3.7M | $-1.2M | ||
| Q2 24 | $-4.7M | — | ||
| Q1 24 | $-7.3M | — |
| Q4 25 | — | -116.5% | ||
| Q3 25 | — | -37.5% | ||
| Q2 25 | — | -28.7% | ||
| Q1 25 | -20.3% | -74.9% | ||
| Q4 24 | -14.1% | -19.4% | ||
| Q3 24 | -46.1% | -14.9% | ||
| Q2 24 | -86.7% | — | ||
| Q1 24 | -92.7% | — |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | 0.2% | 2.2% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 5.6% | 0.1% | ||
| Q2 24 | 9.4% | 0.0% | ||
| Q1 24 | 7.0% | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BRLS
Segment breakdown not available.
CLPT
| Neurosurgery Navigation And Therapy Disposable Products | $4.7M | 45% |
| Biologics And Drug Delivery Services And License Fees | $2.8M | 27% |
| Biologics And Drug Delivery Disposable Products | $2.4M | 23% |
| Other | $502.0K | 5% |
